Anti-VEGF treatment switch in neovascular age-related macular degeneration: a comparison of aflibercept versus ranibizumab after a single-dose switch.

Guillermo Salcedo-VillanuevaEstephania Feria-AnzaldoJuan C Romo-AguasAndrés Lisker-CervantesAlejandra González-DibildoxEdel Moreno-ParamoAbraham A Medina-AndradeRaúl Velez-MontoyaGerardo García-AguirreVirgilio Morales-CantónHugo Quiroz-Mercado

Published in: International ophthalmology (2018)

The effect achieved from a single dose in patients switched to aflibercept or ranibizumab reduced significantly CMT measurements. Comparing aflibercept and ranibizumab, the effect appears to be similar in both drugs, in terms of reduction of CMT.

Keyphrases

age related macular degeneration
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
endothelial cells
peritoneal dialysis